About Cyclin-dependent kinase-like 1
Cyclin-dependent kinase-like 1 (CDKL1) is a protein
from Homo sapiens identified by UniProt accession
Q00532, 357 residues long.
MolForge cross-references it against 0 known binders and
66 disease associations.
Target properties
| Protein name | Cyclin-dependent kinase-like 1 |
| UniProt accession | Q00532 |
| Gene | CDKL1 |
| Organism | Homo sapiens |
| Length | 357 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (66)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.41
- mean corpuscular hemoglobin concentration · score 0.40
- systolic blood pressure · score 0.32
- aspartate aminotransferase measurement · score 0.32
- mean corpuscular hemoglobin · score 0.30
- Palmar Fibromatosis · score 0.25
- Fasciitis · score 0.24
- hemoglobin measurement · score 0.19
- red blood cell density measurement · score 0.17
- vitamin D measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q00532-F1 | alphafold | PREDICTED | 82.18 | — |
Amino-acid sequence (357 residues)
MEKYEKIGKI GEGSYGVVFK CRNRDTGQIV AIKKFLESED DPVIKKIALR EIRMLKQLKH PNLVNLLEVF RRKRRLHLVF EYCDHTVLHE LDRYQRGVPE HLVKSITWQT LQAVNFCHKH NCIHRDVKPE NILITKHSVI KLCDFGFARL LTGPSDYYTD YVATRWYRSP ELLVGDTQYG PPVDVWAIGC VFAELLSGVP LWPGKSDVDQ LYLIRKTLGD LIPRHQQVFS TNQYFSGVKI PDPEDMEPLE LKFPNISYPA LGLLKGCLHM DPTQRLTCEQ LLHHPYFENI REIEDLAKEH NKPTRKTLRK SRKHHCFTET SKLQYLPQLT GSSILPALDN KKYYCDTKKL NYRFPNI
Explore Cyclin-dependent kinase-like 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets